Fifth Third Bancorp’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.04M | Buy |
17,813
+80
| +0.5% | +$14.2K | 0.01% | 902 |
|
|
2026
Q1 | $3.06M | Buy |
17,733
+6,002
| +51% | +$1.11M | 0.01% | 997 |
|
|
2025
Q4 | $2.34M | Sell |
11,731
-661
| -5% | -$120K | 0.01% | 435 |
|
|
2025
Q3 | $1.94M | Sell |
12,392
-479
| -4% | -$76.1K | 0.01% | 480 |
|
|
2025
Q2 | $1.95M | Buy |
12,871
+4,124
| +47% | +$550K | 0.01% | 464 |
|
|
2025
Q1 | $1.32M | Sell |
8,747
-2,030
| -19% | -$340K | 0.01% | 530 |
|
|
2024
Q4 | $1.99M | Sell |
10,777
-3,752
| -26% | -$723K | 0.01% | 444 |
|
|
2024
Q3 | $2.86M | Sell |
14,529
-212
| -1% | -$44.1K | 0.01% | 416 |
|
|
2024
Q2 | $3.05M | Buy |
14,741
+2,055
| +16% | +$466K | 0.01% | 395 |
|
|
2024
Q1 | $3.44M | Buy |
12,686
+624
| +5% | +$149K | 0.01% | 378 |
|
|
2023
Q4 | $2.85M | Buy |
12,062
+580
| +5% | +$114K | 0.01% | 396 |
|
|
2023
Q3 | $2.25M | Sell |
11,482
-22
| -0.2% | -$4.52K | 0.01% | 416 |
|
|
2023
Q2 | $2.42M | Buy |
11,504
+1,714
| +18% | +$341K | 0.01% | 426 |
|
|
2023
Q1 | $1.98M | Buy |
9,790
+1,696
| +21% | +$384K | 0.01% | 447 |
|
|
2022
Q4 | $1.76M | Buy |
8,094
+1,003
| +14% | +$219K | 0.01% | 462 |
|
|
2022
Q3 | $1.4M | Buy |
7,091
+5,754
| +430% | +$1.24M | 0.01% | 483 |
|
|
2022
Q2 | $286K | Buy |
1,337
+599
| +81% | +$146K | ﹤0.01% | 847 |
|
|
2022
Q1 | $210K | Buy |
738
+270
| +58% | +$83.3K | ﹤0.01% | 986 |
|
|
2021
Q4 | $176K | Buy |
468
+104
| +29% | +$40.4K | ﹤0.01% | 1048 |
|
|
2021
Q3 | $150K | Buy |
364
+133
| +58% | +$55.2K | ﹤0.01% | 1054 |
|
|
2021
Q2 | $85K | Buy |
231
+73
| +46% | +$24.4K | ﹤0.01% | 1247 |
|
|
2021
Q1 | $46K | Sell |
158
-96
| -38% | -$26.7K | ﹤0.01% | 1467 |
|
|
2020
Q4 | $63K | Buy |
254
+216
| +568% | +$51.4K | ﹤0.01% | 1292 |
|
|
2020
Q3 | $9K | Sell |
38
-54
| -59% | -$11.2K | ﹤0.01% | 1780 |
|
|
2020
Q2 | $16K | Hold |
92
| – | – | ﹤0.01% | 1599 |
|
|
2020
Q1 | $12K | Hold |
92
| – | – | ﹤0.01% | 1651 |
|
|
2019
Q4 | $14K | Hold |
92
| – | – | ﹤0.01% | 1750 |
|
|
2019
Q3 | $12K | Sell |
92
-20
| -18% | -$2.68K | ﹤0.01% | 1745 |
|
|
2019
Q2 | $16K | Sell |
112
-71
| -39% | -$9.63K | ﹤0.01% | 1691 |
|
|
2019
Q1 | $27K | Sell |
183
-51
| -22% | -$6.7K | ﹤0.01% | 1476 |
|
|
2018
Q4 | $26K | Buy |
234
+51
| +28% | +$6.39K | ﹤0.01% | 1457 |
|
|
2018
Q3 | $25K | Hold |
183
| – | – | ﹤0.01% | 1551 |
|
|
2018
Q2 | $21K | Hold |
183
| – | – | ﹤0.01% | 1643 |
|
|
2018
Q1 | $20K | Buy |
+183
| New | +$19.7K | ﹤0.01% | 1664 |
|
|
2016
Q1 | – | Sell |
-130
| Closed | -$10K | – | 2378 |
|
|
2015
Q4 | $10K | Buy |
130
+1
| +0.8% | +$72 | ﹤0.01% | 1938 |
|
|
2015
Q3 | $8K | Buy |
129
+43
| +50% | +$3.09K | ﹤0.01% | 2103 |
|
|
2015
Q2 | $6K | Sell |
86
-353
| -80% | -$26.1K | ﹤0.01% | 2243 |
|
|
2015
Q1 | $35K | Sell |
439
-341
| -44% | -$25.2K | ﹤0.01% | 1541 |
|
|
2014
Q4 | $50K | Hold |
780
| – | – | ﹤0.01% | 1386 |
|
|
2014
Q3 | $47K | Hold |
780
| – | – | ﹤0.01% | 1409 |
|
|
2014
Q2 | $42K | Sell |
780
-10
| -1% | -$549 | ﹤0.01% | 1494 |
|
|
2014
Q1 | $48K | Buy |
790
+10
| +1% | +$583 | ﹤0.01% | 1436 |
|
|
2013
Q4 | $41K | Hold |
780
| – | – | ﹤0.01% | 1411 |
|
|
2013
Q3 | $36K | Buy |
780
+302
| +63% | +$13.9K | ﹤0.01% | 1449 |
|
|
2013
Q2 | $20K | Buy |
+478
| New | +$20.5K | ﹤0.01% | 1589 |
|
Other funds holding CRL
AI
Fifth Third Bancorp's CRL Position: Q2 2026 in Review
Fifth Third Bancorp increased its Charles River Laboratories (CRL) stake by 0.45% in Q2 2026, buying an estimated $14.2K and bringing the position to 17,813 shares worth $4.04M. The position accounts for 0.01% of the portfolio, ranked #902.
Fifth Third Bancorp first reported a position in CRL in Q2 2013 and has held it in 45 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Fifth Third Bancorp held 17,813 shares of Charles River Laboratories worth $4.04M as of Q2 2026.
- Fifth Third Bancorp bought 80 Charles River Laboratories shares in Q2 2026, an estimated $14.2K.
- Charles River Laboratories made up 0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #902 holding.
- Fifth Third Bancorp first reported a position in Charles River Laboratories in Q2 2013 and has held it in 45 quarters since.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.